Hye In Lim1,2,3, Kazuyuki Hamada4,2, Jun Yamamoto4,2, Qinhong Han4, Yuying Tan4, Hee Jun Choi3, Seok Jin Nam5, Michael Bouvet2, Robert M Hoffman1,2. 1. AntiCancer Inc, San Diego, CA, U.S.A. all@anticancer.com vastprogress@naver.com. 2. Department of Surgery, University of California, San Diego, CA, U.S.A. 3. Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea. 4. AntiCancer Inc, San Diego, CA, U.S.A. 5. Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND/AIM: The aim of the study was to use a triple-negative breast cancer (TNBC) patient-derived orthotopic xenograft (PDOX) model to examine the efficacy of oral recombinant methioninase (o-rMETase) against this recalcitrant disease. MATERIALS AND METHODS: The TNBC tumor from a patient was implanted in the right 4th inguinal mammary fat pad of nude mice. Two weeks later, the mice underwent tumorectomy with grossly-negative surgical margins. Two days after tumorectomy the mice were divided in two groups: one control and one treated with o-rMETase. RESULTS: Tumors recurred in all mice. On day 11, the mean recurrent tumor volumes were 936.7 mm3 in the control group and 450.9 mm3 in the o-rMETase group (p<0.05). On day 15, the mean recurrent tumor volumes were 3392.5 mm3 in the control group and 1603.5 mm3 in the o-rMETase group. The mean recurrent tumor weights were 2.1 g in the control group and 1.1 g in the o-rMETase group on day 15. CONCLUSION: o-rMETase is an effective adjuvant treatment for aggressive TNBC. Copyright
BACKGROUND/AIM: The aim of the study was to use a triple-negative breast cancer (TNBC) patient-derived orthotopic xenograft (PDOX) model to examine the efficacy of oral recombinant methioninase (o-rMETase) against this recalcitrant disease. MATERIALS AND METHODS: The TNBC tumor from a patient was implanted in the right 4th inguinal mammary fat pad of nude mice. Two weeks later, the mice underwent tumorectomy with grossly-negative surgical margins. Two days after tumorectomy the mice were divided in two groups: one control and one treated with o-rMETase. RESULTS: Tumors recurred in all mice. On day 11, the mean recurrent tumor volumes were 936.7 mm3 in the control group and 450.9 mm3 in the o-rMETase group (p<0.05). On day 15, the mean recurrent tumor volumes were 3392.5 mm3 in the control group and 1603.5 mm3 in the o-rMETase group. The mean recurrent tumor weights were 2.1 g in the control group and 1.1 g in the o-rMETase group on day 15. CONCLUSION:o-rMETase is an effective adjuvant treatment for aggressive TNBC. Copyright
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Jun Ho Park; Ming Zhao; Qinghong Han; Yu Sun; Takashi Higuchi; Norihiko Sugisawa; Jun Yamamoto; Shree Ram Singh; Bryan Clary; Michael Bouvet; Robert M Hoffman Journal: Biochem Biophys Res Commun Date: 2019-08-14 Impact factor: 3.575
Authors: Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm Journal: Nat Med Date: 2011-10-23 Impact factor: 53.440
Authors: Aryana M Razmara; Elodie Sollier; Grace N Kisirkoi; Sam W Baker; Margot B Bellon; Alex McMillan; Clementine A Lemaire; Vishnu C Ramani; Stefanie S Jeffrey; Kerriann M Casey Journal: Clin Exp Metastasis Date: 2020-04-25 Impact factor: 5.150
Authors: Hye In Lim; Jun Yamamoto; Qinhong Han; Y U Sun; Hiroto Nishino; Yoshihiko Tashiro; Norihiko Sugisawa; Yuying Tan; Hee Jun Choi; Seok Jin Nam; Michael Bouvet; Robert M Hoffman Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155